seekingalpha.com · 20 jul

Dolby Laboratories Valuation Is Compelling Ahead Of Earnings

Dolby Laboratories is now undervalued after a 50%+ decline from its all-time high, trading at 18.7x FCF and 19.7x earnings. DLB's revenue growth remains choppy, but licensing—especially in Broadcast and Mobile—drives solid results and offers mid-single-digit growth potential. Expansion into automotive and increased adoption of Dolby Atmos/Vision by major platforms and automakers support future growth, with modest price increases feasible.

prnewswire.com · 14 jul

Dolby Laboratories Announces Conference Call and Webcast for Q3 Fiscal 2026 Financial Results

SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2026 after the close of regular trading on Thursday, July 30, 2026. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m.

globenewswire.com · 14 jul

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

seekingalpha.com · 26 jun

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

globenewswire.com · 24 jun

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

zacks.com · 10 jun

3 Audio Video Stocks to Watch as Industry Witnesses Headwinds

Amid cautious discretionary spending and macro troubles, investments in cutting-edge solutions are likely to aid Zacks Audio Video Production industry participants like SONY, DLB and SONO.

gurufocus.com · 9 jun

Arista Introduces Next-Generation 1.6Terabit Portfolio for AI Fabrics

Arista Networks (NYSE: ANET), a leader in modern AI fabric networking, today announced the Arista [url="]7060XE7 Series[/url], a new portfolio of 1.6T networki

gurufocus.com · 5 jun

Dolby Vision and Dolby Atmos to Power Telemundo's FIFA World Cup 2026™ Coverage on Peacock, a Streaming First

Dolby Vision and Dolby Atmos to Power Telemundo's FIFA World Cup 2026™ Coverage on Peacock, a Streaming First PR Newswire